Search
Descriptor English: Trimetrexate
Descriptor Spanish: Trimetrexato
Descriptor Portuguese: Trimetrexato
Descriptor French: Trimétrexate
Entry term(s): CI 898
CI-898
CI898
Hydrate, Trimetrexate
JB 11
JB-11
JB11
Monohydrate, Monoacetate Trimetrexate
NSC 249008
NSC 328564
NSC-249008
NSC-328564
NSC249008
NSC328564
Trimetrexate Hydrate
Trimetrexate Monohydrate, Monoacetate
Tree number(s): D03.633.100.786.925
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D016597
Scope note: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antifungal Agents
Antimetabolites, Antineoplastic
Folic Acid Antagonists
Registry Number: UPN4ITI8T4
CAS Type 1 Name: 2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-
Previous Indexing: Antineoplastic Agents (1966-1991)
Folic Acid Antagonists (1966-1991)
Quinazolines (1966-1991)
Public MeSH Note: 92; TRIMETREXATE was indexed under QUINAZOLINES 1979-91
Online Note: use TRIMETREXATE (NM) to search TRIMETREXATE 1980-91
History Note: 92; was TRIMETREXATE (NM) 1979-91
DeCS ID: 29766
Unique ID: D016597
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1992/01/01
Date of Entry: 1991/01/25
Revision Date: 2017/05/24
Trimetrexate - Preferred
Concept UI M0025316
Scope note A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Preferred term Trimetrexate
JB-11 - Narrower
Concept UI M0353847
Preferred term JB-11
Entry term(s) JB 11
JB11
Trimetrexate Monohydrate, Monoacetate - Narrower
Concept UI M0331295
Preferred term Trimetrexate Monohydrate, Monoacetate
Entry term(s) Monohydrate, Monoacetate Trimetrexate
NSC-328564 - Narrower
Concept UI M0353848
Preferred term NSC-328564
Entry term(s) NSC 328564
NSC328564
Trimetrexate Hydrate - Narrower
Concept UI M0331296
Preferred term Trimetrexate Hydrate
Entry term(s) Hydrate, Trimetrexate
CI-898 - Narrower
Concept UI M0353846
Preferred term CI-898
Entry term(s) CI 898
CI898
NSC-249008 - Narrower
Concept UI M0353849
Preferred term NSC-249008
Entry term(s) NSC 249008
NSC249008



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey